|Bid||742.40 x 0|
|Ask||742.60 x 0|
|Day's Range||738.40 - 747.80|
|52 Week Range||516.20 - 785.40|
|Beta (5Y Monthly)||0.41|
|PE Ratio (TTM)||63.83|
|Forward Dividend & Yield||3.00 (0.42%)|
|Ex-Dividend Date||May 10, 2021|
|1y Target Est||N/A|
In this Motley Fool Live video recorded on Nov. 3, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether investors should have Lonza on their watchlists. Keith Speights: Brian, one final topic before we get to questions.
By Dhirendra Tripathi
Moderna said on Tuesday its COVID-19 vaccine manufacturing partners outside the United States are facing delays due to laboratory testing operations that have occurred in the past few days, slowing the supply of the shot to these markets. The vaccine maker's comments come after South Korean health officials said earlier in the day that Moderna has delayed its late-July vaccine shipment schedule for the country to August due to supply problems. "We are currently not reserving safety stock to allow vaccines to be delivered faster, which means that we do not have stock in storage to smooth these types of shortfalls or delays," a Moderna spokesperson said.